EUVIMEDEUVIMED entdecken
Crossref

Predictors of encapsulated peritoneal sclerosis in patients undergoing peritoneal dialysis using neutral-pH dialysate

Toshiaki Nakano, Hiromasa Kitamura, Shoji Tsuneyoshi, Akihiro Tsuchimoto, Kumiko Torisu, Hiroaki Tsujikawa, Hideki Kawanishi, Kazuhiko Tsuruya, Takanari Kitazono

Clinical and Experimental Nephrology · 2025-02 · 29 (2) · 212-220

DOI: 10.1007/s10157-024-02565-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Nephrology, online erschienen am 04.10.2024. Verfasst von Toshiaki Nakano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, J…. Hauptthemen laut MEDLINE: Peritoneal Dialysis, Dialysis Solutions, Peritoneal Fibrosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Encapsulated peritoneal sclerosis (EPS) is a serious complication in patients undergoing peritoneal dialysis (PD). Neutral-pH dialysate is associated with less peritoneal damage and a lower incidence of EPS than conventional PD solution. However, monitoring for peritoneal damage and predicting EPS remain important during PD therapy. METHODS: We measured the mesothelial cell area, dialysate-to-plasma ratio of creatinine after 4 h, and concentrations of the potential biological markers effluent fibrin degradation products (eFDPs), cancer antigen-125, and interleukin-6 in the effluent dialysate from patients who had been undergoing PD therapy for > 5 years in our hospital. These biomarkers were obtained from the drainage fluid of the final measurement of peritoneal equilibration testing before withdrawal from PD therapy. The concentrations of these potential biomarkers were measured in 39 patients who withdrew from PD therapy and were enrolled in the study. RESULTS: Three participants developed EPS after withdrawing PD. The dialysate-to-plasma ratio of creatinine, area of mesothelial cells, and interleukin-6 appearance rate in participants who developed EPS tended to be higher than those in patients who did not, but there were no significant differences. Significantly more eFDPs were in participants who developed EPS than in those who did not (138.5 ± 15.1 vs. 32.9 ± 7.4 µg/mL, P = 0.002). There was no difference in the cancer antigen-125 appearance rate between the groups. A cut-off value of eFDPs ≥ 119.1 µg/mL was optimal for predicting EPS (P = 0.006, specificity = 0.972, sensitivity = 1.000). CONCLUSION: This study shows that eFDPs may be a useful biological marker for predicting EPS in patients undergoing PD using neutral-pH dialysate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal DialysisDialysis SolutionsPeritoneal FibrosisHumansFemaleMaleMiddle AgedInterleukin-6AgedBiomarkersCreatinineHydrogen-Ion ConcentrationCA-125 AntigenAdultFibrin Fibrinogen Degradation ProductsPredictive Value of TestsMembrane Proteins

Stichwörter der Autor:innen

Biological markerEncapsulated peritoneal sclerosisFibrin degradation productsNeutral-pH dialysatePeritoneal dialysis

Substanzen

Dialysis SolutionsInterleukin-6BiomarkersCreatinineCA-125 AntigenFibrin Fibrinogen Degradation ProductsIL6 protein, humanMUC16 protein, humanMembrane Proteins

Autor:innen und Institutionen

  • Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. nakano.toshiaki.455@m.kyushu-u.ac.jp.
  • Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
  • Department of Internal Medicine, Fukuoka Dental College, Fukuoka, Japan.
  • Department of Integrated Therapy for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Dialysis Division, Tsuchiya General Hospital, Hiroshima, Japan.
  • Department of Nephrology, Nara Medical University, Kashihara, Nara, Japan.

Zitieren

APA

Nakano, T., Kitamura, H., Tsuneyoshi, S., Tsuchimoto, A., Torisu, K., Tsujikawa, H., Kawanishi, H., Tsuruya, K., & Kitazono, T. (2025). Predictors of encapsulated peritoneal sclerosis in patients undergoing peritoneal dialysis using neutral-pH dialysate. Clinical and Experimental Nephrology, 29(2), 212-220. https://doi.org/10.1007/s10157-024-02565-9

Vancouver

Nakano T, Kitamura H, Tsuneyoshi S, Tsuchimoto A, Torisu K, Tsujikawa H, et al. Predictors of encapsulated peritoneal sclerosis in patients undergoing peritoneal dialysis using neutral-pH dialysate. Clinical and Experimental Nephrology. 2025;29(2):212-220. doi:10.1007/s10157-024-02565-9

BibTeX
@article{Nakano2025,
  author = {Nakano, Toshiaki and Kitamura, Hiromasa and Tsuneyoshi, Shoji and Tsuchimoto, Akihiro and Torisu, Kumiko and Tsujikawa, Hiroaki and Kawanishi, Hideki and Tsuruya, Kazuhiko and Kitazono, Takanari},
  title = {Predictors of encapsulated peritoneal sclerosis in patients undergoing peritoneal dialysis using neutral-pH dialysate},
  journal = {Clinical and Experimental Nephrology},
  year = {2025},
  volume = {29},
  number = {2},
  pages = {212--220},
  doi = {10.1007/s10157-024-02565-9}
}
Kostenlos starten →